Livedo reticularis with retiform purpura associated with gefitinib (Iressa®)

International Journal of Dermatology

Volumn 46, Issue 12, 2007, Pages 1307-1308

  Blume, Jonathan E ^a   Miller, Craig C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FUROSEMIDE; GEFITINIB; LOSARTAN;

AGED; ARTICLE; CASE REPORT; DRUG ERUPTION; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVEDO RETICULARIS; MALE; METASTASIS; PROSTATE CANCER; PUNCH BIOPSY; PURPURA; SKIN ULCER; WOUND CARE;

AGED; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; LIVEDO RETICULARIS; MALE; PROSTATIC NEOPLASMS; PURPURA; QUINAZOLINES; SKIN;

EID: 37549007584     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03319.x     Document Type: Article

References (10)

1. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-1218.
2. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23-26.
3. van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601.
4. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Br J Dermatol 2004; 151: 238-241.
5. Ciardiello F, De Vita F, Orditura M, et al. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2004; 16: 130-135.
6. Meropol NJ. Epidermal growth factor receptor inhibitors in colorectal cancer: It's time to get back on target. J Clin Oncol 2005; 23: 1791-1793.
7. Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status predict survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005; 16: 780-785.
8. Gibbs MB, English JC, Zirwas MJ. Livedo reticularis: An update. J Am Acad Dermatol 2005; 52: 1009-1019.
9. Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefitinib (Iressa). Int J Dermatol 2005; 44: 167-168.
10. Kanazawa S, Yamaguchi K, Kinoshita Y, et al. Gefitinib affects functions of platelet and blood vessels via changes in prostanoids balance. Clin Appl Throm Hemost 2005; 11: 429-434.